These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Stein DJ; Andersen EW; Overo KF Braz J Psychiatry; 2007 Dec; 29(4):303-7. PubMed ID: 18200396 [TBL] [Abstract][Full Text] [Related]
23. Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant? Gerra ML; Marchesi C; Amat JA; Blier P; Hellerstein DJ; Stewart JW J Clin Psychiatry; 2014 Sep; 75(9):e939-44. PubMed ID: 25295437 [TBL] [Abstract][Full Text] [Related]
24. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study. Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492 [TBL] [Abstract][Full Text] [Related]
25. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048 [TBL] [Abstract][Full Text] [Related]
26. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. Souery D; Serretti A; Calati R; Oswald P; Massat I; Konstantinidis A; Linotte S; Kasper S; Montgomery S; Zohar J; Mendlewicz J World J Biol Psychiatry; 2011 Aug; 12(5):364-75. PubMed ID: 21718212 [TBL] [Abstract][Full Text] [Related]
27. Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study. Anderberg UM; Marteinsdottir I; von Knorring L Eur J Pain; 2000; 4(1):27-35. PubMed ID: 10833553 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M; Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886 [TBL] [Abstract][Full Text] [Related]
29. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Rampello L; Chiechio S; Nicoletti G; Alvano A; Vecchio I; Raffaele R; Malaguarnera M Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645 [TBL] [Abstract][Full Text] [Related]
30. Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression. Mulert C; Juckel G; Augustin H; Hegerl U Clin Neurophysiol; 2002 Oct; 113(10):1566-72. PubMed ID: 12350432 [TBL] [Abstract][Full Text] [Related]
31. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522 [TBL] [Abstract][Full Text] [Related]
32. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. Arango C; Kirkpatrick B; Buchanan RW J Nerv Ment Dis; 2000 Jan; 188(1):50-3. PubMed ID: 10665462 [No Abstract] [Full Text] [Related]
33. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? Bandelow B; Baldwin DS; Dolberg OT; Andersen HF; Stein DJ J Clin Psychiatry; 2006 Sep; 67(9):1428-34. PubMed ID: 17017830 [TBL] [Abstract][Full Text] [Related]
34. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. Pallanti S; Quercioli L; Bruscoli M J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244 [TBL] [Abstract][Full Text] [Related]
35. Escitalopram : a review of its use in the management of major depressive and anxiety disorders. Waugh J; Goa KL CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Lenze EJ; Mulsant BH; Shear MK; Dew MA; Miller MD; Pollock BG; Houck P; Tracey B; Reynolds CF Am J Psychiatry; 2005 Jan; 162(1):146-50. PubMed ID: 15625213 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. Haffmans PM; Timmerman L; Hoogduin CA Int Clin Psychopharmacol; 1996 Sep; 11(3):157-64. PubMed ID: 8923094 [TBL] [Abstract][Full Text] [Related]
38. Effect of citalopram treatment on relationship between platelet serotonin functions and the Karolinska scales of personality in panic patients. Neuger J; Wistedt B; Aberg-Wistedt A; Stain-Malmgren R J Clin Psychopharmacol; 2002 Aug; 22(4):400-5. PubMed ID: 12172340 [TBL] [Abstract][Full Text] [Related]
39. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Pollock BG; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Huber KA Am J Geriatr Psychiatry; 2007 Nov; 15(11):942-52. PubMed ID: 17846102 [TBL] [Abstract][Full Text] [Related]
40. An index of 5-HT synthesis changes during early antidepressant treatment: alpha-[11C]methyl-L-tryptophan PET study. Berney A; Nishikawa M; Benkelfat C; Debonnel G; Gobbi G; Diksic M Neurochem Int; 2008; 52(4-5):701-8. PubMed ID: 17928105 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]